Hi [[ session.user.profile.firstName ]]

Medical Research

  • Implementing Single-Use PAT at seed stage to simplify cell culture operations
    Implementing Single-Use PAT at seed stage to simplify cell culture operations Dr Jose R. Vallejos Recorded: May 24 2017 35 mins
    Single-Use Process Analytical Technologies (PAT) tools have a great potential to not only increase process understanding at the seed stage but also simplify cell culture operations. By utilizing PAT, the risk from bioburden or contamination can be significantly reduced and the overall operating efficiency increased. In fact, PAT also provides a data-driven platform to integrate Process Development and Manufacturing Operations that can mitigate risks associated with technology/process transfer.
  • From biopsy to treatment: A tissue journey through pathology
    From biopsy to treatment: A tissue journey through pathology Zin Htway, PhD, MBAHM, CT (ASCP, IAC), Maria Magana, Danielle Westfall, MD, Los Robles Hospital and Medical Center Recorded: May 12 2017 43 mins
    Surgical procurement of adequate tissue can be challenging. This presentation will be an in-depth look at rapid on-site evaluation of tissue biopsies from various sites. Best practices for handling, grossing and histology sectioning of tissue biopsies for companion diagnostics will be discussed. This will be followed by a brief overview of this approach applied to immunohistochemistry stains and fluorescence in situ hybridization.
  • Lung Cancer and IHC
    Lung Cancer and IHC Jeff Gordon, Cell Marque- Rocklin, CA Recorded: May 12 2017 67 mins
    Lung cancer is the most commonly diagnosed non-skin cancer in the United States. Each year, over 222,000 people are diagnosed with lung cancer, and over 150,000 succumb each year to the illness, making it also the deadliest cancer in the country. With constant advancement of treatment options, the importance of accurate diagnosis and detection of lung cancer becomes more and more relevant to the survival of the patient. Immunohistochemistry has served as the catalyst for these advancements in lung cancer diagnosis. This presentation covers many of the basic science, facts, and statistics of lung cancer, as well as the utility of immunohistochemical testing with markers such as TTF-1, napsin A, desmoglein-3, and p40 in the accurate diagnosis and survival rates of lung cancer.
  • Publishing Clinic: Write your next paper with success
    Publishing Clinic: Write your next paper with success Dr. José Oliveira, Editor-in-Chief, Small, Wiley and Dr. Patchanita Thamyongkit, Assoc. Professor, Chulalongkorn University Recorded: May 11 2017 60 mins
    Do you find the process of writing a scientific paper unfamiliar and stressful, and wish that there is an expert to guide you through it?
    In this webinar/publishing clinic session, you will learn about top challenges that researchers face when publishing scientific papers, followed by solutions and recommendations by experts in the field.

    Topics covered include:
    - Most-encountered challenges to publishing and how to tackle them
    - Success story: Journey as an early career researcher
    - Success story: Practical tips that worked

    Presented by: Dr. José Oliveira, Editor-in-Chief, Small, Wiley and
    Dr. Patchanita Thamyongkit, Associate Professor, Department of Chemistry, Faculty of Science, Chulalongkorn University
  • The future of the clinical trial – collaboration and patient centricity
    The future of the clinical trial – collaboration and patient centricity Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie Recorded: May 3 2017 73 mins
    Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.

    With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.

    To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
  • Sample Preparation for Food Analysis:  New Technologies and Techniques
    Sample Preparation for Food Analysis: New Technologies and Techniques Jennifer Claus, Product Manager, Franchise Marketing Sample Preparation (Non-Bio) Recorded: Apr 27 2017 75 mins
    In typical analytical workflows, sample preparation accounts for over 60% of the time taken to generate results and 30% of any errors generated. To help analytical chemists maintain the cornerstones of all analytical processes, namely; speed, specificity, sensitivity, and reproducibility, considerable resources have been devoted to the development of new and unique technologies in the sample preparation field. With specific reference to solid phase extraction and solid phase microextraction, this presentation will outline new technologies and techniques developed in sample preparation for food analysis.
  • Simulating MEMS and Smart Materials with COMSOL Multiphysics®
    Simulating MEMS and Smart Materials with COMSOL Multiphysics® Dr Robbie Balcombe, Technical Director, COMSOL Recorded: Apr 27 2017 60 mins
    If you are interested in modelling smart materials and MEMS using COMSOL Multiphysics®, then tune into this webinar.

    Smart materials are materials whose properties or shape respond dynamically to stimuli in their environment. For example, piezoelectric materials experience strain under an applied electric field, while magnetostrictive materials deform in the presence of a magnetic field.

    In this live webinar, you will learn how to model MEMS sensors and actuators based on smart materials for a wide range of applications, including vibration and active shape control as well as structural health monitoring and energy harvesting. We will also demonstrate the applicability of the COMSOL Multiphysics® simulation environment for coupling mechanical, electrical and thermal models of smart materials.

    At the end of this webinar, you can ask questions during the Q&A session.
  • Life sciences promotional content management for speed, compliance and insight
    Life sciences promotional content management for speed, compliance and insight David Bennett, Andrew McConaghie Recorded: Apr 27 2017 69 mins
    The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.

    Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.

    Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.

    From this webinar you will:

    – Learn the current state of commercial content and digital asset management in life sciences promotions
    – Garner an understanding of how your organization compares to the industry
    – Understand how to accelerate your content across the digital supply chain
  • 3 Ways to Retool Your Business with Technology in 2017
    3 Ways to Retool Your Business with Technology in 2017 Andrea Bradbury, Co-Founder and Chief Quality Officer, Suvoda Software; Jeinnfer Royer, Direct Product Marketing, DocuSign Recorded: Apr 25 2017 58 mins
    Nearly 50% of business leaders fear they will become obsolete over the next several years, and nearly 80% feel threatened by digital startups. Why? New technologies and digital strategies are challenging existing business models and forcing companies of all sizes to reimagine patient care, product innovation and distribution models to remain competitive.

    View this on-demand webinar hosted by PharmaVOICE to learn from Andrea Bradbury, Co-Founder and Chief Quality Officer, Suvoda Software, a leader operating at the intersection of life sciences and technology as she shares how she built her business on a digital platform to accelerate her organization’s global expansion while meeting the needs of mobile, digital customers and employees.

    Topics covered include:

    - Streamlining clinical research, sales and HR processes with digital tools
    - Elevating the digital agenda at your organization
    - Scaling technologies globally
    - Applying nimble design models for life science operations
    - Implementing top life sciences trends in 2017
  • Assessing early market opportunity
    Assessing early market opportunity Dominic Tyer Recorded: Apr 19 2017 58 mins
    To successfully develop and launch an asset it’s crucial to identify and define the commercial value early in the process.

    On the 19th April Cello Health, in association with PMGroup, will host a free webinar which will discuss the background and context of early asset development and how to achieve a successful market assessment strategy.

    It will look at how marketers can understand the competitive market landscape as early as possible.
  • Intellectual Property in biotech: from bioprinting to bedside
    Intellectual Property in biotech: from bioprinting to bedside Dr. Scott Collins, President and CTO of TeVido Recorded: Apr 12 2017 31 mins
    TeVido BioDevices uses the innovative process of 3D bioprinting living human cells for use as implants or grafts for use in reconstructive surgery and wound care, for example in post-surgery care for cancer patients.

    TeVido uses a simple yet sophisticated approach to produce living tissue products - inkjet printers modified to print cells instead of ink.
    In this live webinar, Dr. Scott Collins, CTO and VP of Research and Development at TeVido, will explain TeVido’s innovation journey, from concept, through research and prototying, to funding, patenting, and testing the company’s highly innovative offering in the field of biotechnology.
  • When small becomes big: orphan medicines, advances, access and affordability
    When small becomes big: orphan medicines, advances, access and affordability Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah Recorded: Apr 10 2017 75 mins
    Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
    On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe in the context of changes in reimbursement processes and broader future challenges, like Brexit.
  • Disruptive forces in technology and the implications for healthcare
    Disruptive forces in technology and the implications for healthcare Fonny Schenck (CEO Across Health) Recorded: Apr 4 2017 45 mins
    Live Webinar on April 4 at 5pm CET
    Life Sciences is an industry full of established, large companies with significant barriers to entry and often long legacies of success. But the weather is changing – and the structures and strategies which have kept these enterprises safe may soon become liabilities. What is only just becoming clear, though, is how fast this is happening. Along all key areas of the value chain, new & nimble competitors are entering the scene - and they are playing a totally different game.

    Find out more about these disruptive trends, get the highlights of our second ‘Healthcare Disruption Tour’, which went to the heart of the action in Jan 2017, and learn why pharma should take note…and how it can best prepare & organize for this tsunami.

    Topics:
    • Key trends in healthcare disruption
    • Impressions from the second healthcare disruption tour
    • Embedding disruption in pharma organisations
  • Single Use Systems in Biologics Manufacturing & their Impact on Operational Tech
    Single Use Systems in Biologics Manufacturing & their Impact on Operational Tech Gloria Gadea-Lopez, John Maguire, Mark Maselli & Ken Clapp Recorded: Apr 4 2017 62 mins
    The increased interest and adoption of single use systems (SUS) or disposables require that organizations rethink their operational business processes and the design and configuration of manufacturing execution systems (MES). Drawing from their previous experience implementing MES and SUS for biologics manufacturing, the authors discuss the key areas of impact of SUS on operational technology, outline new user requirements, and propose practical solutions for successful MES implementation.
  • Enabling CAR-T Screening in 3D Tumor Spheroids
    Enabling CAR-T Screening in 3D Tumor Spheroids Van Dang, D.V.M., Ph.D., Abhi Saharia, Ph. D., and Audrey Bergeron, Applications Scientist Recorded: Mar 30 2017 62 mins
    Webinar Date & Time: Mar 30 2017 12:00 p.m. EST

    Chimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown promise to affect complete remission in patients with B-cell malignancies. However, applying this approach to target solid tumors has resulted in adverse effects in clinical studies. Methods for testing different models of CAR-T cells in vitro can provide further insight into viable antigen targets. Historically, two-dimensional (2D) cell culture models have been used in drug discovery. However, more elaborate, three-dimensional (3D) cell culture models better mimic the in vivo tumor microenvironment and help bridge the gap between in vitro studies and clinical outcomes.

    In this special joint webinar, panelists from ProMab Biotechnologies, DiscoverX, and Corning Life Sciences will present data on a high-throughput, easy-to-use, highly reproducible method for screening CAR-T cells in a 3D cell culture model by combining various technologies.


    Speakers:
    Van Dang, D.V.M., Ph.D.
    Scientist and coordinator for CAR-T research
    ProMab Biotechnologies, Inc.

    Abhi Saharia, Ph. D.
    Director, Cell-based Assays and Biologics
    DiscoverX

    Audrey Bergeron
    Applications Scientist
    Corning Life Sciences
  • Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers
    Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers Yaso Natkunam, MD, PhD, Professor of Pathology, Director of Hematopathology, Stanford University School of Medicine Recorded: Mar 29 2017 58 mins
    Join us for the March CDx Insights webinar “Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers.” Our speaker is Yaso Natkunam, MD, PhD, Professor of Pathology and Director of Hematopathology at Stanford University School of Medicine. Dr Natkunam will review key updates to the classifications of large B-cell lymphomas in the “2016 revision of the World Health Organization classification of lymphoid neoplasms.” She will also discuss the role of diagnostic and predictive biomarkers in DLBCL, high grade B-cell lymphoma and other large B-cell lymphomas.
  • Biosimilars - A Network perspective
    Biosimilars - A Network perspective Divya Chadha Manek Recorded: Mar 29 2017 15 mins
    A biosimilar medicine is a biological medicine which is highly similar to another biological medicine already licensed for use. It is a biological medicine which has been shown not to have any clinically meaningful differences from the originator biological medicine in terms of quality, safety and efficacy.
  • Unlocking the value of pharmacists to reach the right patients and consumers
    Unlocking the value of pharmacists to reach the right patients and consumers Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie Recorded: Mar 29 2017 70 mins
    Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
    Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
    We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
    Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
    •The challenges of identifying the right patient population across European markets
    •Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
    •How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
  • NIHR Clinical Research Network support for Biosimilars clinical trials
    NIHR Clinical Research Network support for Biosimilars clinical trials Dr Sonya Abraham, Consultant Research Physician and Rheumatologist Recorded: Mar 29 2017 16 mins
    This presentation will discuss NIHR Clinical Research Network support for Biosimilar clinical trials. It begins with a background to biosimilars and the changing landscape in their drug development and regulatory pathways. It then focuses on the opportunities that the NHS via the NIHR CRNs can engage in biosimilar clinical trials across therapeutic indications.
  • Analytical Strategies for Comparability in Bioprocess Development
    Analytical Strategies for Comparability in Bioprocess Development Christine P. Chan, Ph.D & Joe Barco, Ph.D. Recorded: Mar 28 2017 71 mins
    Comparability exercises are commonly required at certain milestones during drug development as well as after product registration when changes are implemented into the manufacturing process. The goal is to evaluate if the product remains highly similar (not necessarily identical) before and after the change in terms of quality and stability and have no adverse impact on safety and efficacy predicted for the patients. This assessment requires product-specific knowledge gathered through drug development, taking a totality-of-evidence approach. The different levels of information are obtained from analytical studies for characterization of the molecule, animal studies for toxicity, pharmacokinetics and pharmacodynamics for pharmacological activities, and clinical studies for safety/tolerability, immunogenicity and efficacy. This Webinar discusses strategies and considerations for analytical characterization of protein structure and function which forms the foundation of the comparability demonstration.

    Sponsored by Unchained Labs

    Presentation Title: Limber up your lab with better tools for comparing biologics

    There’s no magic bullet when it comes to characterizing a protein by structure or function. Specific tests may work for one molecule but not the next. Instrumentation that provides a high degree of flexibility, balanced with low sample consumption and faster time to result, is crucial to keep up with ever changing laboratory needs. Unchained Labs puts biologics characterization front and center for our instrumentation development. We will discuss how our instruments let researchers be more flexible and efficient, while also providing clear data to help make comparability assessments.
  • 2017 Frost & Sullivan Predictions in Diagnostics
    2017 Frost & Sullivan Predictions in Diagnostics Transformational Health Team, Harry Glorikian, Board Advisor and Eunice Teo, Director, Business Development, QuantuMDx Recorded: Mar 23 2017 64 mins
    The global clinical diagnostics industry is undergoing a transformation propelled by laboratory consolidation and automation, an enormous move toward data-driven healthcare, large investments in unifying technologies, and renewed business models driven by products and value-added services. There is immense pressure on companies to radically improve new product innovation, manufacturing, and distribution of technologies such as point-of-care molecular diagnostics to capture new growth opportunities in the precision medicine market.
  • Diagnostic and Therapeutic Patent and License Strategies
    Diagnostic and Therapeutic Patent and License Strategies Dr. Lisa Haile, Co-Chair, Global Life Sciences Sector at DLA Piper Recorded: Mar 22 2017 48 mins
    Dr Lisa Haile presents this webinar exploring issues and strategies for diagnostic and therapeutic patents and licenses.

    This webinar will address questions such as:
    Are diagnostic tests patentable?
    What are the effects of the Alice ruling and the Myriad Genetics case on patents?
    What strategies can be used to avoid the pitfalls associated with patenting around "laws of nature"?
    What are the latest rulings and precedents around diagnostics and genetic markers and how is the landscape evolving?

    This is essential viewing for anyone involved with intellectual property and innovation in the life sciences sector.
  • Introduction to Publishing for Early Career Researchers in Latin America
    Introduction to Publishing for Early Career Researchers in Latin America Dr Costas Agalou, Dr Serena Tan, Eduardo Martinez, Vicky Kinsman Recorded: Mar 22 2017 61 mins
    Learn more about the process of writing and submitting your research with practical tips on selecting the right journal, writing your article, understanding the peer review process and post-publication SEO and promotion. Register for your place today and discover all you need to help you successfully publish your next article.

    Discover all you need to know to start publishing with success!
    Do you struggle to find the right journal?
    Do you want advice on how to write and submit your paper?
    Do you want to understand the peer review process?
    Would you like tips on how to how to maximize the impact of your research?

    …then join our webinar and ask our expert editors, Dr Costas Agalou and Dr. Serena Tan, your questions.
  • The medical physics revolution continues:  the next 60 years
    The medical physics revolution continues: the next 60 years Robert Jeraj, Professor, Medical Physics, University of Wisconsin Recorded: Mar 22 2017 48 mins
    In the fifth and final of our series of webinars showcasing presentations from the PMB 60th Anniversary Symposium, Robert Jeraj from the University of Wisconsin takes a look at what may lie ahead for medical physics in the next 60 years.
  • Studentship opportunities with the UK National Quantum Technology Hubs
    Studentship opportunities with the UK National Quantum Technology Hubs Professor Kai Bongs, Professor Miles Padgett, Professor Ian Walmsley, Professor Tim Spiller May 25 2017 2:00 pm UTC 60 mins
    The UK Quantum Technology Hubs led by the Universities of Birmingham, Glasgow, Oxford and York are offering fully funded PhD studentships in the areas of sensing and metrology, enhanced imaging, quantum computing and secure communications, Find out more about each hub’s research and their partners, and the studentship opportunities available.

    The UK Quantum Technology Hubs are part of the UK government’s £270 million National Quantum Technologies Programme set up to exploit the potential of quantum science and develop a range of emerging technologies with the potential to benefit the UK.
  • The benefits of gigahertz mode spacing for frequency comb applications
    The benefits of gigahertz mode spacing for frequency comb applications Dr Albrecht Bartels, managing director of Laser Quantum May 30 2017 2:00 pm UTC 60 mins
    After the first demonstration of an optical frequency comb based on a mode-locked laser in 1999, Ti:sapphire lasers with repetition rates around 1 GHz were the sources of choice for scientists around the world. Their key feature was a mode spacing 10 times higher than that of comparable 100 MHz sources (simplifying mode identification) and the ability to generate a fully coherent super-continuum with 100 times more power per mode either directly from the cavity or using an external microstructured fibre (enhancing signal-to-noise ratio). The world’s first optical atomic clock was built in 2001 using a 1 GHz Ti:sapphire laser and subsequently it has been shown that these lasers indeed support an accuracy at the 10–20 level with a 1 s stability at the 10–17 level and optical linewidths at the millihertz level, i.e. ideal candidate clockworks for a new generation of optical atomic clocks. The Ti:sapphire technology has even been taken out to as far as 10 GHz, a regime where individual modes with powers in excess of 1 mW can be separated with a grating spectrometer and used individually for direct spectroscopy, spectrograph calibration or optical arbitrary waveform generation.

    To overcome some of the disadvantages of early Ti:sapphire lasers (requirement for frequent alignment, cleaning and use of AO modulators for control purposes) and to make the full advantages of GHz frequency comb technology accessible to the science community, Laser Quantum has developed the hermetically sealed and permanently aligned taccor 1 GHz Ti:sapphire laser featuring an integrated pump laser with direct pump power control. This intervention free laser forms the basis for the new taccor comb system featuring an f-2f interferometer and full comb-stabilization electronics.

    This webinar reviews the benefits of gigahertz Ti:sapphire frequency combs and focuses on the recent progress using Laser Quantum‘s hermetically sealed line of taccor lasers.
  • Multichannel Rep
    Multichannel Rep Annelien Van Boxlaer (VP Innovation Strategy, Across Health) & Patrick Vidal (MD, Across Health France) May 30 2017 3:00 pm UTC 60 mins
    The world of the field force is changing. Increased digitalisation, powerful new tools and a growing expectation that they ‘conduct’ multiple channels means new skills, ways of working, and even thinking, are needed.

    This shift will radically change the structure of the traditional Pharma organization. Differences between HQ and local offices will become less pronounced as the field force gains the ability to deploy highly tailored, right-on-time content, in the best possible format for individual physicians.

    Find out more about how the time of the Multichannel Rep is now, how upskilling and reskilling are the buzzwords for new engagement models, and how not to have your field force being left behind in the digital race!

    Topics include:
    •Getting the right digital tools into the hands of reps
    •How to evaluate what the best channels for your situation are
    •Finding out what good looks like
    •How to engage your field force, manage the change, and sustain their motivation
  • Basic Principles of Solid Phase Microextraction (SPME) Method Development
    Basic Principles of Solid Phase Microextraction (SPME) Method Development Emanuela Gionfriddo, Ph.D.; Research Associate under Prof. Janusz Pawliszyn, University of Waterloo (ON, Canada) May 31 2017 1:30 pm UTC 75 mins
    For the past two decades, Solid Phase Microextraction (SPME) has represented a convenient alternative to conventional sample prep procedures. SPME allows the simultaneous extraction and enrichment of analytes of interest from a given matrix in a single step while avoiding, or drastically minimizing, the use of organic solvents and time-consuming cleanup procedures.
    Like any other analytical method, the various parameters governing the SPME process need to be carefully optimized in order to achieve robustness and sensitivity. However, certain aspects of SPME method development are often overlooked by many users, leading to unsatisfactory performance of the technique.
    This webinar will shed light into several aspects of SPME method development. The presentation will include a theoretical explanation of SPME fundamentals and practical suggestions to overcome common errors and bias encountered when using SPME.
    The webinar is divided in three main sections: 1) optimization of extraction conditions 2) matrix modifications 3) optimization of desorption conditions for gas and liquid chromatography. Each section is divided in various subsections dedicated to each parameter affecting the performance of the SPME technique. The webinar attendees will be guided through comprehensive understanding of the technology and the critical parameters that influence the extraction process with practical examples from already existing methods.
  • Chemicals and Patents: Using IP insights to stay ahead of the competition
    Chemicals and Patents: Using IP insights to stay ahead of the competition Duncan Clark, Head of Product Marketing at patsnap.com May 31 2017 3:00 pm UTC 60 mins
    While innovation intelligence provides a wealth of data regarding future drug possibilities and their attachment to therapeutic areas, this information can be difficult to extract and integrate into workflows and processes. As such, it is hard for organizations to formulate a targeted strategy based on all the information available.

    In this webinar, we will be investigating the ever increasing pressure to improve collaborative efficiency between R&D, IP and other divisions within pharmaceutical organizations in order to drive successful drug discovery and commercialization.

    We will also be discussing:

    - Approaches that can be taken to overcome these difficulties
    - Steps that can be taken to align all teams during the entire phase of discovery & commercialization
    - How to use innovation data systematically to drive further success and explore new opportunities
  • Tools For Assessing Iron Status
    Tools For Assessing Iron Status Eloísa Urrechaga, M.D., Ph.D. May 31 2017 6:00 pm UTC 75 mins
    In this webinar, Eloísa Urrechaga, M.D., Ph.D., will discuss the importance of iron status assessment in accurately diagnosing and treating anemia. The complexities of anemia require solutions that will help meet the daily challenges of distinguishing iron deficiency anemia (IDA) and isolating anemia of chronic diseases (ACD) from the combined state of IDA/ACD.

    After this webinar, you will be able to:

    • Discuss current advancements in anemia diagnosis
    • More clearly understand the role of accurate iron status assessment
    • Cite the latest research experience with Beckman Coulter analyzers in assessing iron status

    P.A.C.E. credit is available for your participation.*

    Presenter:
    Eloísa Urrechaga, M.D., Ph.D., has more than 30 years of experience in hematology and laboratory medicine. She is a specialist in clinical analysis technology, robotics in hematology, iron and anemia, erythropoiesis and glycohemoglobin. Currently, Dr. Urrechaga is responsible for the hematology laboratory at the Hospital Galdakao-Usansolo in Spain.

    Dr. Urrechaga contributes her expertise to the Spanish Science and Innovation Ministry by assessing new technologies. She also provides counsel to the Health Research Council for the validation of research projects in the Czech Republic and Argentina. In addition, she is a member of several international organizations, such as the World Health Organization Guideline Development Group and European Network for Rare and Congenital Anaemias. Dr. Urrechaga also serves as an editorial board member and scientific reviewer for a number of journals.
  • バイオ医薬品製造におけるシングルユースシステム
    バイオ医薬品製造におけるシングルユースシステム コーニングインターナショナル株式会社ライフサイエンス事業部 石渡孝至 Jun 6 2017 6:00 am UTC 75 mins
    バイオロジクスの治験薬製造におけるシングルユース技術導入ポイントであります製品ソリューション、クローズドシステムおよび品質保証体制について概説します。

    再生・細胞医薬を中心にバイオ医薬品の製造開発が急速に進められております。

    幹細胞やヒトES / iPS細胞による再生医療を具現化する際に、最も大きな懸案事項となりますのが“質”、“量”そして“コスト”の問題があります。

    そこでコーニングは、安全、安価かつ簡便な最新シングルユース技術についてレギュレーション、導入事例によるマーケットトレンドを示しながら、トータルソリューションシステムのセルカルチャー(多層式大量培養容器)、チュービング&コネクション(プレアッセンブル特注、無菌接続)、パッケージング(培養 / 回収 / 凍結保存)、データインテグリティ(バーコードによるトレーサビリティ管理)、品質規格(成型施設環境、BSE/TSE、発熱物質(Pyrogen)、USPクラス6規格準拠 / 滅菌保証レベル / エンドトキシン規格 / QC試験)および品質に関するドキュメンテーションサポート(証明書、バリデーションバインダ)に関する情報を概説します。
  • Challenges in the Development of Continuous Processes for Vaccines
    Challenges in the Development of Continuous Processes for Vaccines Danny Vellom Jun 7 2017 2:00 pm UTC 75 mins
    The development and application of continuous manufacturing processes for vaccines presents both great opportunity as well as significant challenges, both technical and cultural, for the global industry. The key drivers are manufacturing capacity and flexibility, speed to market, and improved quality through the application of Quality-by-Design and Process Analytical Technology (QbD/PAT). Given the diversity of immunogens (toxoids, conjugate and subunit vaccines, live-attenuated and inactivated viruses, VLPs, etc.), and the variety of unique processes currently utilized to produce either single- or multi-component vaccines, it is unlikely that the transition to continuous processing will happen overnight. Additionally, cultural challenges are faced whenever a new mode of operation appears to some as “too different”, especially in a traditionally conservative sector like the developed-world vaccine industry. That said, market forces, global climate change, and Nature’s propensity to fill unoccupied niches with emerging infectious diseases will undoubtedly induce a first round of pioneers to explore this exciting new design space, ultimately leading to a more nimble industry and more and better opportunities for protection for the global population.
  • Photonics Simulation with COMSOL Multiphysics®
    Photonics Simulation with COMSOL Multiphysics® Simone Zonetti, Applications Engineer, COMSOL Jun 8 2017 1:00 pm UTC 60 mins
    If you are interested in learning about photonics simulation using the COMSOL Multiphysics® software, then tune into this webinar.

    Photonics (the generation, detection, and manipulation of light) plays a fundamental role in modern technology. It is used in a wide range of applications, such as telecommunications, medicine, computing, and manufacturing.

    During this webinar, we will discuss using COMSOL Multiphysics® for photonics simulations, in particular periodic structures and crystals. We will show how modeling can provide insight into the design and characterisation of photonic devices. This includes solving for the propagation of electromagnetic waves, even in the presence of wavelength-dependent material properties, as well as multiphysics effects like heating or mechanical loading.

    The webinar includes a live demonstration and a Q&A session during which you can ask questions.
  • New 3D-Printable Hydrogel-Based and Particle-Based Biomaterial Ink Platforms
    New 3D-Printable Hydrogel-Based and Particle-Based Biomaterial Ink Platforms Ramille Shah and Adam Jakus Jun 12 2017 3:00 pm UTC 75 mins
    3D-printing has emerged as a very promising fabrication platform for complex tissue engineering. However, a significant limitation is the availability of biomaterial inks that can be 3D-printed into highly, biologically functional materials and structures. Join us as Professor Ramille Shah and Dr. Adam Jakus of the Shah TEAM Laboratory of The Shah Tissue Engineering and Additive Manufacturing (TEAM) Laboratory discuss their work to expand the current 3D-printable material toolbox. They will review not only the an extensive variety of tailorable, functional, and clinically friendly biomaterials and corresponding medical constructs, but also additional materials, such as metals, alloys, graphene, and ceramics.

    Topics will include:
    •Two new, distinct 3D-printable material platforms, Hydrogel Bioprinting and 3D-Painting, that have been developed and extended to create hundreds of distinct 3D-printable materials.
    • The unique and advantageous properties of the new materials
    • Specific examples of new 3D-printable material systems including, new hydrogels for liver, kidney, and ovarian tissue and organ engineering and 3D-painted Hyperelastic “Bone”, 3D-Graphene
  • Powering pharma’s commercial teams with market access insights
    Powering pharma’s commercial teams with market access insights Paul Tunnah, Lance Scott, others tbc Jun 12 2017 7:00 pm UTC 75 mins
    Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans. Biopharma companies must take into account a multitude of factors when considering physician prescribing behaviors, and need a more integrated "pull-through" strategy across their teams, from managed markets, to marketing, to field sales. Just as an engine needs a steady supply of fuel to run efficiently, prescriber-facing teams – the commercial engine of life sciences companies – need market access data and insights to accelerate brand success. Today, the challenge is optimizing this fuel supply, as market access and commercial teams often operate in a siloed way with regards to data, market changes and insights.
    Join a vibrant conversation with industry leaders to discuss how the industry is changing and adapting to operationalize market access pull-through for improved commercial success.
  • Amplified Detection of Proteins and their Interactions using Duolink PLA
    Amplified Detection of Proteins and their Interactions using Duolink PLA Manpreet Mutneja, Ph.D, MBA Sr. Product Manager, Molecular Platforms Life Science Research, MilliporeSigma Jun 15 2017 5:00 pm UTC 75 mins
    Understanding the movements, modifications and interactions of proteins within a cell is key to unraveling the fundamental tenets of biology. However, the low-level expression of many proteins, combined with the transient nature of their interactions and movements, makes analyzing and understanding these processes quite difficult. Duolink® PLA, which is based on the principles of the proximity ligation assay (PLA), offers a solution to overcome these hurdles and to study the actions of endogenous proteins within cells and tissues. Combining the specificity of antibodies with the sensitivity afforded by rolling circle amplification, Duolink® PLA allows you to detect, visualize, and quantitate proteins and their interactions (even single events) where they happen within cells or tissue, all without overexpression or genetic manipulation. This seminar will cover the basic assay principle and advantages of the Duolink® PLA technology, and discuss recent applications and developments of the technology that make it an excellent tool to understand the fundamental mechanisms of biology, as well as disease states. Applications of Duolink® PLA include the investigation of cellular responses to varying stimuli, receptor dimerization and signalling cascades, post-translational modifications, and regulation of protein expression. New developments include use in flow cytometry and multiplexed detection.
  • Winning Westerns: Proven Strategies to Optimize Your Western Blots
    Winning Westerns: Proven Strategies to Optimize Your Western Blots Natasha L. Pirman, Ph.D. Jun 21 2017 3:00 pm UTC 75 mins
    Does western blotting give you more trouble than expected? Do you feel like your precious samples are being wasted on bad westerns? Join us and find out how you can improve your western blots! In this seminar, you will learn general guidelines for performing and troubleshooting your westerns, such as:

    • Choice of different blotting membranes
    • Parameters affecting blotting efficiency
    • Conditions for optimizing your immunodetection
    • Information on SNAP i.d.® 2.0 system: A faster way to perform immunodetection
  • Immuno-PET with Nanobodies
    Immuno-PET with Nanobodies Dr Hidde Ploegh, Senior Investigator, Boston Children’s Hospital Jun 22 2017 3:00 pm UTC 60 mins
    The ability to visualize immune responses non-invasively would have tremendous value for basic immunology. In pre-clinical models it would be possible to track events such as the host response to infections, to look at inflammation more generally, and to follow the course of interventions such as checkpoint blocking antibodies in the treatment of tumours.

    PET imaging agents require a workflow compatible with the half-life of commonly used isotopes, and must take into account the pharmacokinetic properties of these agents. The specificity of what is being imaged requires the design of compounds that can distinguish between differences in metabolic activity (18F-fluorodeoxyglucose) or that serve as ligands for specific receptors, such as antibodies that recognize surface structures. We have used nanobodies, the smallest antibody-derived fragments that retain antigen-binding capacity. These fragments are ~15 kDa in size, are rapidly cleared from the circulation and are easily modified by chemo-enzymatic means for the installation of metal chelators or click handles to enable radiolabelling. Using nanobodies, we have been able to image various populations of immune cells, and based on longitudinal immuno-PET observations we have been able to make predictions of success and failure in immunotherapy of the B16 mouse melanoma model. The use of 89Zr-labelled nanobodies for immuno-PET will be a powerful adjunct to more conventional, invasive models, and will provide resolution superior to fluorescence- and luminescence-based models.
  • Advanced Cell Culture Technology for Generation of In Vivo-like Tissue Models
    Advanced Cell Culture Technology for Generation of In Vivo-like Tissue Models Stefan Przyborski, PhD - Professor of Cell Technology, Durham University UK Jun 30 2017 2:00 pm UTC 75 mins
    The benefits of three dimensional (3D) cell culture are widely appreciated. More cell-based technologies are now becoming available that enable researchers to preserve the native 3D structure of cells in vitro. These can be broadly divided into three areas: aggregate-based methods; hydrogels and extra-cellular matrices; and inert scaffold-based technologies. Each has strengths and weaknesses and there is no one technology that satisfies all applications. Tissues in the body are mostly composed of different cell types that are often highly organized in relation to each other. Often cells are arranged in distinct layers that enable signalling and cell-to-cell interactions. Alternatively in tumours, cancer cells form aggregates and tissue masses composed of different cell types. Recreation of these types of architecture will significantly evolve 3D cell culture to a new level where real tissue-like structures can be generated in vitro.

    This webinar will review the alternative approaches available to researchers and provide an overview of their capabilities and example applications. More sophisticated models are developing as 3D cell culture technology becomes established and accepted as a means of creating more physiologically relevant cell-based assays. Methods that are relatively straightforward to use and that recreate the organized structure of real tissues will become valuable research tools for use in discovery, validation studies, and modelling disease.

    Key areas covered:
    • 2D vs 3D cell culture debate
    • Review of alternative approaches and the development of new technologies
    • Challenges facing 3D culture methods, in terms of technologies available and methods used
    • Showcase applications where 3D technology makes a difference
    • Future perspective for 3D cell culture technology and further development
  • Modernizing Biopharmaceutical Manufacturing: From Batch to Continuous Production
    Modernizing Biopharmaceutical Manufacturing: From Batch to Continuous Production Robert Dream Jul 19 2017 2:00 pm UTC 75 mins
    The importance and value of continuous bioprocessing, both upstream and downstream has economic and sustainability advantages and due to the modular nature of continuous bioprocesses means that industry is able to adapt more rapidly to changing market demands. Continuous biopharmaceutical manufacturing in the context of other industries that have already successfully adopted continuous processing. Factor other than scientific ones, are the barriers to change from batch to continuous production. an excellent example of the manufacturing strategies of the steel industry in the 20th century, when this industrial sector incrementally switched from batch to continuous operations. biopharmaceutical industry has reached a stage that requires a change in the production paradigm. For a certain class of biopharmaceutical products upstream continuous manufacturing has always been applied: for example, unstable proteins that rapidly degrade in the culture broth. In order to obtain a high quality product, the residence time in the reactor must be minimized. This can only be achieved with continuous cultivation and preferably with perfusion reactors. a brief overview on the types of cell retention devices currently used in biopharmaceutical industry.
    Furthermore, this is a universal production platform that can be extended to other classes of products, such as antibodies, which are relatively stable molecules. continuous manufacturing is as productive and with a much smaller footprint of the manufacturing plant, avoiding multiple non-value added unit operations. In essence, the investment for a continuous plant is much smaller compared to a batch-operated one.
  • New Paradigm of Building Quality during Manufacture - Challenges with Biologics
    New Paradigm of Building Quality during Manufacture - Challenges with Biologics Dr Rajesh K. Gupta Aug 23 2017 2:00 pm UTC 75 mins
    Historically, quality of biological products has been ensured through testing representative samples. Shift in quality paradigm started with implementation of Good Manufacturing Practice (GMP) regulations with current focus on building quality during manufacture. Inherent variability and complexity of biological products pose challenges in implementing Quality by design (QbD) concept. This presentation discusses ways to build quality during manufacture of biological products.
  • Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug
    Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug Arnaud Delobel, PhD Sep 12 2017 2:00 pm UTC 75 mins
    ADCs are complex compounds resulting from the coupling of cytotoxic small molecules to a monoclonal antibody. Their characterization as well as their bioanalysis (quantification in biological fluids) remains challenging. Mass spectrometry at different levels (intact, middle, peptide) can be a valuable tool, and can now be used in a regulated environment thanks to advances in both hardware and software.
  • Single-Use Stainless Steel BioReactors: Quality Factors for Consideration When S
    Single-Use Stainless Steel BioReactors: Quality Factors for Consideration When S Dr Trevor Deeks, Principal and Consultant of Deeks Pharmaceutical Consulting Services, LLC Nov 8 2017 3:00 pm UTC 75 mins
    Single-use (SU) systems are now in common use in pharmaceutical bioprocessing, as well as in other related technologies such as the manufacture of diagnostics and other biological products, and their popularity is increasing. Some types of SU systems have been in use for many decades now. The earliest SU systems being disposable filter cartridges that do not require a stainless steel (SS) filter housing. This present article seeks to focus in particular on SU bioreactors for cell culture and bacterial fermentation for the purpose of producing therapeutic proteins, monoclonal antibodies and vaccines. SU bioreactors are of particular value in early phase (Clinical Phases 1 and 2) GMP manufacturing. In some cases their use has now stretched through into commercial processing, albeit that the scale of operation is currently limited and in general the largest commercially available SU bioreactors are around 2000L working volume (WV). However, the small footprint that they require, and the reduction in investment needed for support services and utilities, means that the scale limitations can be overcome to a significant degree by having multiple SU bioreactors operating in parallel within a facility. The harvest from multiple bioreactors can be pooled for downstream processing, or each harvest can be processed as a separate batch, based upon considerations of the risks versus the economies of pooling.
  • Can the New generation of perfusion technology compete or replace the convention
    Can the New generation of perfusion technology compete or replace the convention Ankur Bhatnagar Nov 15 2017 10:00 am UTC 75 mins
    Recently, there has been a renewed interest in the field of continuous processing. Some key factors driving this interest are – availability of better cell retention devices, improved cell lines and culture medium capable of supporting high cell densities.

    These factors have contributed mainly in reducing the batch duration for making the required quantity of product, thus reducing the medium requirement and chances of batch failures significantly. With the continuous processing being considered as ‘back-in-the-game’, the question remains: Can the current perfusion technology compete or replace the conventional and widely preferred fed-batch technology?

    Two cases are discussed to compare the performance features of fed-batch and perfusion processes. In both the cases, the product output from perfusion process is significantly higher (2 to 5 folds) than that from fed-batch, due to combination of factors like higher cell density, higher cell specific productivity, lower accumulation of toxic metabolites etc. These cases demonstrate the potential of perfusion process in significantly increasing the product output. However, there are certain challenges and points to be considered before a company decides to switch to a perfusion platform. Some of these are highlighted in the article.